The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“VISA was also described in ST1-IV, ST30-IV, ST59-IV, ST72-IV, ST81-IV, ST45, ST228-I, ST398, ST900-III, ST1301-II [84,85,86,87].”
From Molecular Mechanisms of Drug Resistance in Staphylococcus aureus (2022) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Re-Evaluation of Random-Effects Meta-Analysis
Higgins, J. P. T., Thompson, S. G., & Spiegelhalter, D. J. (2009) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2008.00552.x · Cited by 2,569 · cited 1×
“As in previous meta-analyses in which unexplained heterogeneity was identified, we accommodated this condition by using REM, in which the effects underlying the results of different studies are assumed to be drawn from a normal distribution [124].”
MethodWootton, M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.399 · Cited by 414
Fridkin, S. K., Hageman, J., McDougal, L. K., Mohammed, J., Jarvis, W. R., Perl, T. M., Tenover, F. C., & the Vancomycin‐Intermediate Staphylococcus aureus Epidemiology Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/346207 · Cited by 344
Research works printed but not linked: 121
- FD Lowy, 1998, Staphylococcus aureus infections, The New England journal of medicine, 339, 520, 10.1056/NEJM199808203390806 · DOI · Paper page
- CL M, 2007, Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections, Emerg Infect Dis, 13, 236, 10.3201/eid1302.060781 · DOI · Paper page
- M LC, 2006, Trends in Antimicrobial Resistance in Health Care-Associated Pathogens and Effect on Treatment, Clinical Infectious Diseases, 42
- KS Kaye, 2004, Reference group choice and antibiotic resistance outcomes, Emerging infectious diseases, 10, 1125, 10.3201/eid1006.020665 · DOI
- K. H, 2001, Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance, The Lancet Infectious Diseases, 1, 147, 10.1016/S1473-3099(01)00091-3 · DOI · Paper page
- SK Fridkin, 2001, Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know, Clin Infect Dis, 32, 108, 10.1086/317542 · DOI · Paper page
- K H, 1998, The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan, The American Journal of Medicine, 5A, 7S
- MJ R, 2001, Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options, Drugs, volume 61, 1, 10.2165/00003495-200161010-00001 · DOI
- SJv Hal, 2011, Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates, Antimicrob Agents Chemother, 55, 405, 10.1128/AAC.01133-10 · DOI · Paper page
- J Ariza, 1999, Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin, Lancet, 353, 1587, 10.1016/S0140-6736(99)01017-X · DOI · Paper page
- MN Kim, 2000, Vancomycin-intermediate Staphylococcus aureus in Korea, Journal of clinical microbiology, 38, 3879, 10.1128/JCM.38.10.3879-3881.2000 · DOI
- LH Sng, 2005, Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore, International journal of antimicrobial agents, 25, 177, 10.1016/j.ijantimicag.2004.11.001 · DOI
- C Liu, 2003, Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods, Antimicrob Agents Chemother, 47, 3040, 10.1128/AAC.47.10.3040-3045.2003 · DOI · Paper page
- N Mantel, 1959, Statistical aspects of the analysis of data from retrospective studies of disease, Journal of the National Cancer Institute, 15, 639
- R Dersimonian, 1986, N: Meta-analysis in clinical trials, Controlled Clinical Trials
- JP Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med, 21, 1539, 10.1002/sim.1186 · DOI · Paper page
- MF Freeman, 1950, Transformations Related to the Angular and the Square Root, ANNALS OF MATHEMATICAL STATISTICS, 6, 180
- F Garnier, 2006, A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital, The Journal of antimicrobial chemotherapy, 57, 146, 10.1093/jac/dki413 · DOI
- H Hanaki, 2014, Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011, Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy, 20, 527, 10.1016/j.jiac.2014.06.012 · DOI
- SS W, 1999, Bacteremia caused by staphylococci with inducible vancomycin heteroresistance, Clinical Infectious Diseases, 29, 760, 10.1086/520429 · DOI · Paper page
- MJ Rybak, 2008, Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007), Journal of clinical microbiology, 46, 2950, 10.1128/JCM.00582-08 · DOI
- M Pastagia, 2009, Clinical and bacteriologic characteristics of a 5-year cohort of MRSA patients at a large U.S. metropolitan hospital, Clinical Microbiology and Infection, 15, S20
- RK Fong, 2009, Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore, European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology, 28, 983, 10.1007/s10096-009-0741-5 · doi:10.1007/s10096-009-0741-5
- PG C, 2004, Clinical Features Associated with Bacteremia Due to Heterogeneous Vancomycin-Intermediate Staphylococcus aureus, Clinical Infectious Diseases, 38, 448, 10.1086/381093 · DOI · Paper page
- Y Maor, 2009, Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia, The Journal of infectious diseases, 199, 619, 10.1086/596629 · DOI · Paper page
- PR Hsueh, 2010, Clonal dissemination of meticillin-resistant and vancomycin-intermediate Staphylococcus aureus in a Taiwanese hospital, International journal of antimicrobial agents, 36, 307, 10.1016/j.ijantimicag.2010.06.035 · DOI
- MN Kim, 2002, Clonal Spread of Staphylococcus aureus Heterogeneously Resistant to Vancomycin in a University Hospital in Korea, Journal of clinical microbiology, 40, 1376, 10.1128/JCM.40.4.1376-1380.2002 · DOI
- KH Park, 2012, Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus, The Journal of antimicrobial chemotherapy, 67, 1843, 10.1093/jac/dks131 · DOI
- C Hafer, 2012, Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus, Antimicrobial agents and chemotherapy, 56, 5845, 10.1128/AAC.01139-12 · DOI
- A dL, 2006, Control And Outcome Of A Large Outbreak Of Colonization And Infection With Glycopeptide-Intermediate Staphylococcus Aureus In An Intensive Care Unit, Clinical Infectious Diseases, 42, 170, 10.1086/498898 · DOI
- F Kaleem, 2012, Current status of Glycopeptide intermediate and heterogenous Glycopeptide intermediate Staphylococcus aureus and their prevailing susceptibility pattern at two tertiary care hospitals of Pakistan, International Journal of Infectious Diseases, 16, e420, 10.1016/j.ijid.2012.05.582 · doi:10.1016/j.ijid.2012.05.582
- J Robert, 2006, Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983–2002, The Journal of antimicrobial chemotherapy, 57, 506, 10.1093/jac/dki486 · DOI
- HJ Adam, 2010, Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995–2006, Antimicrobial agents and chemotherapy, 54, 945, 10.1128/AAC.01316-09 · DOI
- T Takata, 2009, Detection of Heterogeneous Vancomycin Intermediate Staphylococcus aureus (hetero-VISA) in MRSA of Japanese Clinical Isolates, American Journal of Infection Control, 37, E15, 10.1016/j.ajic.2009.04.011 · doi:10.1016/j.ajic.2009.04.011
- SS Richter, 2011, Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States, Journal of clinical microbiology, 49, 4203, 10.1128/JCM.01152-11 · DOI
- K Hiramatsu, 1997, Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin, The Lancet, 350, 1670, 10.1016/S0140-6736(97)07324-8 · DOI · Paper page
- SJ Van Hal, 2011, Emergence and evolution of heteroresistant vancomycin intermediate Staphylococcus aureus in a single hospital over a 12-year period, Clinical Microbiology and Infection, 17, S58
- JH Song, 2004, Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin, Antimicrobial agents and chemotherapy, 48, 4926, 10.1128/AAC.48.12.4926-4928.2004 · DOI
- R Geisel, 1999, Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area, The Journal of antimicrobial chemotherapy, 43, 846, 10.1093/jac/43.6.846 · DOI · Paper page
- S Gowrishankar, 2013, Emergence of methicillin-resistant, vancomycin-intermediate Staphylococcus aureus among patients associated with group A Streptococcal pharyngitis infection in southern India, Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases, 14, 383, 10.1016/j.meegid.2013.01.002 · doi:10.1016/j.meegid.2013.01.002
- O Denis, 2002, Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features, Journal of Antimicrobial Chemotherapy, 50, 383, 10.1093/jac/dkf142 · DOI
- T Lewis, 2009, Epidemiology of MRSA bacteraemia and clinical relevance of reduced susceptibility to vancomycin, Clinical Microbiology and Infection, 15, S544
- AM Casapao, 2014, Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus, Antimicrobial agents and chemotherapy, 58, 4636, 10.1128/AAC.02820-13 · DOI
- S Trakulsomboon, 2001, First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand, Journal of clinical microbiology, 39, 591, 10.1128/JCM.39.2.591-595.2001 · DOI
- A Lulitanond, 2009, The first vancomycin-intermediate Staphylococcus aureus strains isolated from patients in Thailand, Journal of clinical microbiology, 47, 2311, 10.1128/JCM.01749-08 · DOI
- A K, 2004, Frequency of Reduced Vancomycin Susceptibility and Heterogeneous Subpopulation in Persistent or Recurrent Methicillin-Resistant Staphylococcus aureus Bacteremia, Clin Infect Dis, 38, 1328, 10.1086/383036 · DOI
- MD El Ayoubi, 2014, Glycopeptide intermediate Staphylococcus aureus and prevalence of the luk-PV gene in clinical isolates, in Northern Lebanon, Medecine et maladies infectieuses, 44, 223, 10.1016/j.medmal.2014.03.004 · DOI
- SK H, 1999, Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals, Journal of clinical microbiology, 3590
- A M, 2000, Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital, Journal of clinical microbiology, 2, 866
- CN Chaudhari, 2015, Heterogeneous vancomycin-intermediate among methicillin resistant Staphylococcus aureus, Medical journal, Armed Forces India, 71, 15, 10.1016/j.mjafi.2014.03.008 · DOI
- F Campanile, 2010, Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates, International journal of antimicrobial agents, 36, 415, 10.1016/j.ijantimicag.2010.06.044 · DOI
- A Delgado, 2007, Hetero-vancomycin-intermediate methicillin-resistant Staphylococcus aureus isolate from a medical center in Las Cruces, New Mexico, Journal of clinical microbiology, 45, 1325, 10.1128/JCM.02437-06 · DOI
- I Uckay, 2012, High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus, Antimicrobial agents and chemotherapy, 56, 1258, 10.1128/AAC.05808-11 · DOI
- JL Wang, 2013, High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients, International journal of antimicrobial agents, 42, 390, 10.1016/j.ijantimicag.2013.07.010 · DOI
- H-m Neoh, Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections, Annals of Clinical Microbiology and Antimicrobials, 6, 13
- K Kosowska-Shick, 2008, Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center, Antimicrobial agents and chemotherapy, 52, 4510, 10.1128/AAC.01073-08 · DOI
- H Chen, 2011, The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC, Diagnostic microbiology and infectious disease, 71, 301, 10.1016/j.diagmicrobio.2011.06.010 · DOI
- ME Reverdy, 2001, Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals, Clinical Microbiology and Infection: the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 7, 267, 10.1046/j.1198-743x.2001.00256.x · DOI
- MM Fitzgibbon, 2007, Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus, Journal of clinical microbiology, 45, 3263, 10.1128/JCM.00836-07 · DOI
- Y Nakipoglu, 2005, Investigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospital, BMC infectious diseases, 5, 31, 10.1186/1471-2334-5-31 · DOI
- AC Silveira, 2014, Is prediffusion test an alternative to improve accuracy in screening hVISA strains and to detect susceptibility to glycopeptides/lipopeptides?, Diagnostic microbiology and infectious disease, 79, 401, 10.1016/j.diagmicrobio.2014.04.008 · DOI
- JM E, 2005, Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area, Clinical Infectious Diseases, 40, 1617, 10.1086/429906 · DOI
- SL Fink, 2012, Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans, Antimicrobial agents and chemotherapy, 56, 582, 10.1128/AAC.05024-11 · DOI
- C N, 2005, Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals, Clinical Microbiology and Infection, 11, 214, 10.1111/j.1469-0691.2004.01060.x · DOI
- GL C, 2004, Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals, Clinical Microbiology and Infection, 10, 448, 10.1111/j.1469-0691.2004.00830.x · DOI
- B Sancak, 2005, Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital, The Journal of antimicrobial chemotherapy, 56, 519, 10.1093/jac/dki272 · DOI
- P Panomket, 2014, Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Sanprasitthiprasong Hospital, Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 97, S7
- WY Wang, 2009, Molecular and phenotypic characteristics of methicillin-resistant and vancomycin-intermediate staphylococcus aureus isolates from patients with septic arthritis, Journal of clinical microbiology, 47, 3617, 10.1128/JCM.00539-09 · DOI
- C Liu, 2014, Molecular characteristics and virulence factors in methicillin-susceptible, resistant, and heterogeneous vancomycin-intermediate Staphylococcus aureus from central-southern China, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
- SY Lin, 2012, Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 45, 435, 10.1016/j.jmii.2012.05.004 · DOI
- HB Kim, 2003, Nationwide Surveillance for Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Korea, Journal of clinical microbiology, 41, 2279, 10.1128/JCM.41.6.2279-2281.2003 · DOI
- G Chung, 2010, Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006, Journal of microbiology and biotechnology, 20, 637
- Y Ike, 2001, Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals, Journal of clinical microbiology, 39, 4445, 10.1128/JCM.39.12.4445-4451.2001 · DOI
- H Hanaki, 2007, Occurrence of vancomycin-intermediate-resistant Staphylococcus aureus in Japan, Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy, 13, 118, 10.1007/s10156-006-0498-Z · DOI
- HS Sader, 2009, Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals, The Journal of antimicrobial chemotherapy, 64, 1024, 10.1093/jac/dkp319 · DOI
- S Parer, 2012, An outbreak of heterogeneous glycopeptide-intermediate Staphylococcus aureus related to a device source in an intensive care unit, Infection control and hospital epidemiology, 33, 167, 10.1086/663703 · DOI
- A N, 2012, The presence of heterogeneous vancomycin-lntermediate Staphylococcus aureus (heteroVISA) in a major Malaysian hospital, The Medical journal of Malaysia
- G B, 1999, Presence of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Germany, European Journal of Clinical Microbiology and Infectious Diseases, 18, 691, 10.1007/s100960050380 · DOI
- CM Ho, 2010, Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aureus among methicillin-resistant isolates in Taiwan—SMART program, 2003, European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology, 29, 383, 10.1007/s10096-009-0868-4 · DOI
- Y Maor, 2007, Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center, Journal of clinical microbiology, 45, 1511, 10.1128/JCM.01262-06 · DOI
- W Sun, 2009, Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China, Antimicrobial agents and chemotherapy, 53, 3642, 10.1128/AAC.00206-09 · DOI
- Y W, 2013, Prevalence and clinical prognosis of heteroresistant vancomycin-intermediate Staphylococcus aureus in a tertiary care center in China, Chin Med J (Engl), 126, 505, 10.3760/cma.j.issn.0366-6999.20120812 · doi:10.3760/cma.j.issn.0366-6999.20120812
- M Chaudhary, 2013, Prevalence of heterogeneous glycopeptide intermediate resistance in Methicillin-Resistant Staphylococcus aureus, American Journal of Infectious Diseases, 9, 63, 10.3844/ajidsp.2013.63.70 · DOI
- P Vaudaux, 2012, Prevalence of isolates with reduced glycopeptide susceptibility in orthopedic device-related infections due to methicillin-resistant Staphylococcus aureus, European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology, 31, 3367, 10.1007/s10096-012-1705-8 · DOI
- B Khanal, 2010, Prevalence of Vancomycin Intermediate Staphyloccus aureus (VISA) in a tertiary care hospital in Eastern Nepal, International Journal of Infectious Diseases, 14, e342, 10.1016/j.ijid.2010.02.381 · doi:10.1016/j.ijid.2010.02.381
- F Bert, 2003, Prevalence, Molecular Epidemiology, and Clinical Significance of Heterogeneous Glycopeptide-Intermediate Staphylococcus aureus in Liver Transplant Recipients, Journal of clinical microbiology, 41, 5147, 10.1128/JCM.41.11.5147-5152.2003 · DOI
- KC Horne, 2009, Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA, Antimicrobial agents and chemotherapy, 53, 3447, 10.1128/AAC.01365-08 · DOI
- R Canton, 1999, Prospective study of Staphylococcus aureus with reduced susceptibility to glycopeptides, Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia, 12, 48
- M K, 1999, Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus, The Journal of antimicrobial chemotherapy, 43, 729, 10.1093/jac/43.5.729 · DOI
- R Khatib, 2011, Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia, The Journal of antimicrobial chemotherapy, 66, 1594, 10.1093/jac/dkr169 · DOI
- HA Bataineh, 2006, Resistance of Staphylococcus aureus to vancomycin in Zarqa, Jordan, Pakistan Journal of Medical Sciences, 22, 144
- SR Ramli, 2012, Screening and detection of heterogenous vancomycin intermediate Staphylococcus aureus in Hospital Kuala Lumpur Malaysia, using the glycopeptide resistance detection Etest and population analysis profiling, Infectious disease reports, 4, e20, 10.4081/idr.2012.3836 · doi:10.4081/idr.2012.3836
- D Pierard, 2004, Screening for Staphylococcus aureus with a reduced susceptibility to vancomycin in: a Belgian hospital, Pathologie-biologie, 52, 486, 10.1016/j.patbio.2004.07.016 · DOI
- A Mlynarczyk, 2003, Searching for Staphylococcus aureus strains with reduced susceptibility to glycopeptides among clinical isolates obtained during the year of 2002, Medycyna doswiadczalna i mikrobiologia, 55, 209
- D F, 1999, Seeking Vancomycin Resistant Staphylococcus aureus among Patients with Vancomycin-Resistant Enterococci, Clinical Infectious Diseases, 29, 1566, 10.1086/313530 · DOI
- A Kirby, 2010, Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK, The Journal of antimicrobial chemotherapy, 65, 721, 10.1093/jac/dkq009 · doi:10.1093/jac/dkq009
- D Dubey, 2013, Surveillance of infection status of drug resistant Staphylococcus aureus in an Indian teaching hospital, Asian Pacific Journal of Tropical Disease, 3, 133, 10.1016/S2222-1808(13)60057-2 · DOI
- Y Guo, 2013, A surveillance study of antimicrobial resistance of gram-positive cocci strains isolated from 16 teaching hospitals in China in 2012, Chinese Journal of Microbiology and Immunology (China), 33, 401
- F-J Schmitz, 1999, Susceptibility of 302 methicillin-resistant Staphylococcus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds, European Journal of Clinical Microbiology and Infectious Diseases, 18, 528, 10.1007/s100960050340 · doi:10.1007/s100960050340
- HM A, 2000, Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus, The Journal of antimicrobial chemotherapy, 46, 639, 10.1093/jac/46.4.639-a · doi:10.1093/jac/46.4.639-a
- B S, 2013, Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey, BMC infectious diseases, 13, 46
- J Ariza, 1999, Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin, The Lancet, 353, 1587, 10.1016/S0140-6736(99)01017-X · DOI · Paper page
- AC Musta, 2009, Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years, Journal of clinical microbiology, 47, 1640, 10.1128/JCM.02135-08 · DOI
- SM Tallent, 2002, Vancomycin Susceptibility of Oxacillin-Resistant Staphylococcus aureus Isolates Causing Nosocomial Bloodstream Infections, Journal of clinical microbiology, 40, 2249, 10.1128/JCM.40.6.2249-2250.2002 · DOI
- AM Pitz, 2011, Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates, Journal of clinical microbiology, 49, 269, 10.1128/JCM.00914-10 · DOI
- MN Kim, 2000, Vancomycin-intermediate Staphylococcus aureus in Korea, Journal of clinical microbiology, 38, 3879, 10.1128/JCM.38.10.3879-3881.2000 · DOI
- M Pastagia, 2012, Predicting risk for death from MRSA bacteremia, Emerging Infectious Diseases, 18, 1072, 10.3201/eid1807.101371 · DOI
- G CG, 2004, Glycopeptide resistance in Staphylococcus aureus: is it a real threat?, Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy, 10, 69, 10.1007/s10156-004-0307-5 · DOI
- Y T, 2011, Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia, Journal of Infection and Chemotherapy, 17, 52, 10.1007/s10156-010-0086-0 · DOI
- CL Moore, 2012, Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study, Clin Infect Dis, 54, 51, 10.1093/cid/cir764 · DOI · Paper page
- FC Tenover, 2001, Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus, Emerg Infect Dis, 7, 327, 10.3201/eid0702.010237 · DOI · Paper page
- M Saito, 2014, "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3, Antimicrobial agents and chemotherapy, 58, 5024, 10.1128/AAC.02470-13 · doi:10.1128/aac.02470-13
- PL Ho, 2010, Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong, The Journal of infection, 60, 140, 10.1016/j.jinf.2009.11.011 · doi:10.1016/j.jinf.2009.11.011
- W Chang, 2015, Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China, Indian journal of medical microbiology, 33, 262, 10.4103/0255-0857.148837 · DOI
- CJ Chen, 2014, New epidemiology of Staphylococcus aureus infection in Asia, Clin Microbiol Infect, 20, 605, 10.1111/1469-0691.12705 · DOI · Paper page
- Y K, 2000, A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus, Antimicrobial agents and chemotherapy, 44, 1549, 10.1128/AAC.44.6.1549-1555.2000 · DOI · Paper page
- TS N, 2003, Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection, JAMA, 290, 2976, 10.1001/jama.290.22.2976 · DOI · Paper page
- SL K, 2006, In vitro exposure of community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains to vancomycin: does vancomycin resistance occur?, International journal of antimicrobial agents, 27, 168, 10.1016/j.ijantimicag.2005.10.009 · DOI
- J E, 2013, Carriage frequency, diversity and methicillin resistance of Staphylococcus aureus in Danish small ruminants, Veterinary Microbiology, 163, 110, 10.1016/j.vetmic.2012.12.006 · DOI
- M Aires de Sousa, 2005, Comparison of genetic backgrounds of methicillin-resistant and -susceptible Staphylococcus aureus isolates from Portuguese hospitals and the community, Journal of clinical microbiology, 43, 5150, 10.1128/JCM.43.10.5150-5157.2005 · DOI
- M L, 2012, MRSA epidemic linked to a quickly spreading colonization and virulence determinant, Nature Medicine, 18, 816, 10.1038/nm.2692 · DOI · Paper page
Cited by
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Mechanisms and clinical relevance of bacterial heteroresistance
Andersson, D. I., Nicoloff, H., & Hjort, K. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0218-1 · Cited by 513
Vancomycin resistance in Staphylococcus aureus
Appelbaum, P. C., & Bozdogan, B. (2004) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2004.03.004 · Cited by 485
Yeh, Y.-C., Huang, T.-H., Yang, S.-C., Chen, C.-C., & Fang, J.-Y. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00286 · Cited by 416
Molecular Mechanisms of Drug Resistance in Staphylococcus aureus
Mlynarczyk-Bonikowska, B., Kowalewski, C., Krolak-Ulinska, A., & Marusza, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158088 · Cited by 412
Metadata
- Authors
- Zhang, S., Sun, X., Chang, W., Dai, Y., & Ma, X.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-08-19
- Volume
- 10
- Issue
- 8
- Pages
- e0136082
- ISSN
- 1932-6203
- Cited by
- 99
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates. https://app.cochat.ai/papers/10.1371/journal.pone.0136082
- The paper
- Zhang, S., Sun, X., Chang, W., Dai, Y., & Ma, X. (2015). Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates. PLOS ONE. https://doi.org/10.1371/journal.pone.0136082
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.